N-GRANULE Trademark

Trademark Overview

On Thursday, May 25, 2023, a trademark application was filed for N-GRANULE with the United States Patent and Trademark Office. The USPTO has given the N-GRANULE trademark a serial number of 98014263. The federal status of this trademark filing is SU - RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Tuesday, April 21, 2026. This trademark is owned by Nano PharmaSolutions, Inc.. The N-GRANULE trademark is filed in the Pharmaceutical Products category with the following description:

Drug intermediates, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals
n-granule

General Information

Serial Number98014263
Word MarkN-GRANULE
Filing DateThursday, May 25, 2023
Status814 - SU - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateTuesday, April 21, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 7, 2024

Trademark Statements

Goods and ServicesDrug intermediates, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 27, 2023
Primary Code005
First Use Anywhere DateSunday, August 31, 2025
First Use In Commerce DateSunday, August 31, 2025

Trademark Owner History

Party NameNano PharmaSolutions, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
US
Party NameNano PharmaSolutions, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121
US

Trademark Events

Event DateEvent Description
Monday, May 29, 2023NEW APPLICATION ENTERED
Tuesday, June 27, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, February 16, 2024ASSIGNED TO EXAMINER
Tuesday, February 20, 2024NON-FINAL ACTION WRITTEN
Tuesday, February 20, 2024NON-FINAL ACTION E-MAILED
Tuesday, February 20, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 3, 2024EXAMINERS AMENDMENT -WRITTEN
Wednesday, April 3, 2024EXAMINERS AMENDMENT E-MAILED
Wednesday, April 3, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, April 3, 2024EXAMINER'S AMENDMENT ENTERED
Wednesday, April 3, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 17, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 7, 2024PUBLISHED FOR OPPOSITION
Tuesday, May 7, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 2, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, July 3, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 3, 2024SOU EXTENSION 1 FILED
Wednesday, July 3, 2024SOU EXTENSION 1 GRANTED
Wednesday, July 3, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 13, 2025SOU TEAS EXTENSION RECEIVED
Tuesday, May 13, 2025SOU EXTENSION 2 FILED
Tuesday, May 13, 2025SOU EXTENSION 2 GRANTED
Wednesday, May 14, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 22, 2025TEAS STATEMENT OF USE RECEIVED
Wednesday, April 8, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, October 22, 2025USE AMENDMENT FILED
Thursday, April 9, 2026STATEMENT OF USE PROCESSING COMPLETE
Friday, April 10, 2026SU - NON-FINAL ACTION - WRITTEN
Friday, April 10, 2026NON-FINAL ACTION E-MAILED
Friday, April 10, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 14, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, April 17, 2026ASSIGNED TO LIE
Tuesday, April 21, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 21, 2026TEAS/EMAIL CORRESPONDENCE ENTERED

Related Keywords

granule delivery drug wide range pharmaceuticals facilitate consisting intermediates namely agents